OncoSil Medical Limited (ASX:OSL)

Market Cap	36.30M +76.9%
Revenue (ttm)	5.23M +221.5%
Net Income	-10.86M
EPS	-0.48
Shares Out	30.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,473
Open	1.170
Previous Close	1.150
Day's Range	1.160 - 1.175
52-Week Range	0.370 - 2.090
Beta	1.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OSL

Financial Performance

In fiscal year 2026, OncoSil Medical's revenue was 5.23 million, an increase of 240.57% compared to the previous year's 1.54 million. Losses were -10.86 million, -28.08% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 28, 2026

Data Sources Report a data error